S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.26 (+3.19%)
AAPL   146.09 (+2.56%)
MSFT   249.11 (+3.48%)
META   140.34 (+1.25%)
GOOGL   101.64 (+3.04%)
AMZN   121.08 (+4.49%)
TSLA   249.48 (+2.92%)
NVDA   131.70 (+5.26%)
NIO   16.73 (+8.01%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.08 (+1.13%)
MU   54.02 (+4.45%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.75 (+12.65%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.26 (+3.19%)
AAPL   146.09 (+2.56%)
MSFT   249.11 (+3.48%)
META   140.34 (+1.25%)
GOOGL   101.64 (+3.04%)
AMZN   121.08 (+4.49%)
TSLA   249.48 (+2.92%)
NVDA   131.70 (+5.26%)
NIO   16.73 (+8.01%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.08 (+1.13%)
MU   54.02 (+4.45%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.75 (+12.65%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.26 (+3.19%)
AAPL   146.09 (+2.56%)
MSFT   249.11 (+3.48%)
META   140.34 (+1.25%)
GOOGL   101.64 (+3.04%)
AMZN   121.08 (+4.49%)
TSLA   249.48 (+2.92%)
NVDA   131.70 (+5.26%)
NIO   16.73 (+8.01%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.08 (+1.13%)
MU   54.02 (+4.45%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.75 (+12.65%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.26 (+3.19%)
AAPL   146.09 (+2.56%)
MSFT   249.11 (+3.48%)
META   140.34 (+1.25%)
GOOGL   101.64 (+3.04%)
AMZN   121.08 (+4.49%)
TSLA   249.48 (+2.92%)
NVDA   131.70 (+5.26%)
NIO   16.73 (+8.01%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.08 (+1.13%)
MU   54.02 (+4.45%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.75 (+12.65%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
OTCMKTS:PURE

PURE Bioscience - PURE Stock Forecast, Price & News

$0.20
0.00 (0.00%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.19
$0.20
50-Day Range
$0.20
$0.23
52-Week Range
$0.15
$0.40
Volume
954 shs
Average Volume
140,443 shs
Market Capitalization
$17.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PURE stock logo

About PURE Bioscience (OTCMKTS:PURE) Stock

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

Receive PURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.

PURE Stock News Headlines

Algorithms & stats are now core to research
Stocks in play: Isracann Biosciences Inc
PURE Biosciences Inc
PURE Bioscience Reports Fiscal 2021 Financial Results
AstraZeneca (AZN) shares gain on acquisition news
See More Headlines
Receive PURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.

PURE Company Calendar

Last Earnings
3/12/2020
Today
10/04/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PURE
Employees
10
Year Founded
N/A

Profitability

Net Income
$-2,320,000.00
Net Margins
-131.59%
Pretax Margin
-131.59%

Debt

Sales & Book Value

Annual Sales
$3.93 million
Book Value
$0.04 per share

Miscellaneous

Free Float
63,148,000
Market Cap
$17.60 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Tom Y. Lee CPA (Age 73)
    CEO, Pres & Director
    Comp: $64k
  • Mr. Mark Stuart Elliott (Age 47)
    VP of Fin. and Principal Financial & Accounting Officer
    Comp: $162k
  • Mr. Thomas Richard Myers (Age 69)
    COO & Director
    Comp: $200k
  • Dr. Zhinong Yan
    Exec. VP of Technology & Bus. Devel.
  • Mr. John Kasperski
    VP of Sales













PURE Stock - Frequently Asked Questions

How have PURE shares performed in 2022?

PURE Bioscience's stock was trading at $0.19 on January 1st, 2022. Since then, PURE stock has increased by 5.2% and is now trading at $0.1999.
View the best growth stocks for 2022 here
.

Are investors shorting PURE Bioscience?

PURE Bioscience saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 21,500 shares, a drop of 40.9% from the August 31st total of 36,400 shares. Based on an average daily trading volume, of 456,900 shares, the days-to-cover ratio is currently 0.0 days.
View PURE Bioscience's Short Interest
.

When is PURE Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our PURE earnings forecast
.

How were PURE Bioscience's earnings last quarter?

PURE Bioscience, Inc. (OTCMKTS:PURE) released its earnings results on Thursday, March, 12th. The company reported ($0.01) earnings per share for the quarter. The firm earned $0.35 million during the quarter. PURE Bioscience had a negative net margin of 131.59% and a negative trailing twelve-month return on equity of 131.39%.

What other stocks do shareholders of PURE Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PURE Bioscience investors own include NVIDIA (NVDA), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), Riot Blockchain (RIOT), Enphase Energy (ENPH), Mastercard (MA), Main Street Capital (MAIN), Twilio (TWLO) and

What is PURE Bioscience's stock symbol?

PURE Bioscience trades on the OTCMKTS under the ticker symbol "PURE."

How do I buy shares of PURE Bioscience?

Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PURE Bioscience's stock price today?

One share of PURE stock can currently be purchased for approximately $0.20.

How much money does PURE Bioscience make?

PURE Bioscience (OTCMKTS:PURE) has a market capitalization of $17.60 million and generates $3.93 million in revenue each year. The company earns $-2,320,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How can I contact PURE Bioscience?

PURE Bioscience's mailing address is 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.purebio.com. The company can be reached via phone at (619) 596-8600, via email at melliott@purebio.com, or via fax at 619-596-8790.

This page (OTCMKTS:PURE) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.